Emicizumab
Hemlibra (emicizumab-kxwh) is a prescription medication used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with hemophilia A (congenital factor VIII deficiency), both with and without factor VIII inhibitors. It is a bispecific monoclonal antibody that mimics the function of factor VIII by simultaneously binding to factor IXa and factor X, thereby restoring the impaired clotting cascade in people with hemophilia A. This medication is administered as a subcutaneous (under the skin) injection, typically given once weekly, every two weeks, or every four weeks based on the prescribed dosing schedule.
Hemlibra is a prophylactic treatment for hemophilia A that works as a bispecific antibody to help restore normal blood clotting, given as a subcutaneous injection.
Key facts at a glance
- RxNorm
- 1989800
- Generic
- Hemlibra
- Class
- brand-name
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Hemlibra is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency), including those with acquired factor VIII inhibitors (neutralizing antibodies). It may be used in all age groups.
Hemlibra is a bispecific monoclonal antibody that simultaneously binds to factor IXa and factor X, mimicking the cofactor function of endogenous factor VIII. This bridges the activation of factor X by factor IXa, thereby restoring the functionality of the impaired intrinsic tenase complex and facilitating normal blood clotting.
Hemlibra is administered via subcutaneous injection only—it is not given intravenously. Patients or caregivers can be trained to administer it at home. Important safety considerations include the risk of thrombotic microangiopathy and thrombotic events when used with activated prothrombin complex concentrate (aPCC), and it does not correct underlying factor VIII deficiency, so it should not be used to treat acute bleeding episodes. Regular monitoring by a healthcare provider is required.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy